Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock
Role and Regulation of p65/-Catenin association during liver injury and regeneration: A Complex relationship
The trial followed 54 healthy adults over six months, dividing them into a placebo group, a low-dose group (250 mg/day), and a high-dose group (1000 mg/day), meticulously tracking glutathione levels across multiple cellular compartments, as detailed in the published clinical trial
257, L163L173
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
US$ 25.52
US$ 23.06
US$ 20.28
US$ 26.77
